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Abstract 
A correlation between high plasma serotonin levels and total pulmonary resistance was reported 
in more than 80% of pulmonary hypertensive patients. When submitted to chronic hypoxia (10% 
O2 for more than 3 weeks), wildtype mice develop lung vascular remodeling and pulmonary 
hypertension. We previously reported that, by contrast, the development of these hypoxia-
dependent alterations is totally abolished in mice with permanent (genetic) or transient 
(pharmacologic) inactivation of the serotonin 5-HT2B receptor. In the present study, we asked 
whether 5-HT2B receptors could be involved in the control of plasma serotonin levels. Further 
investigating the chronic-hypoxic-mouse model of pulmonary hypertension, we first show that in 
wildtype mice, plasma serotonin levels and 5-HT2B receptors expression were significantly 
increased after chronic exposure to hypoxia. This increase appeared before significant changes in 
remodeling factors could be detected and persisted when the pathology was established. 
Conversely, in mice with either genetically or pharmacologically inactive 5-HT2B receptors, 
plasma serotonin levels were not modified by chronic hypoxia. We then confirmed that 5-HT2B 
receptors can control plasma serotonin levels by providing in vivo evidence that an acute agonist 
stimulation of 5-HT2B receptor triggers a transient increase in plasma serotonin that is serotonin 
transporter dependent and blocked by 5-HT2B receptor selective antagonist or genetic abalation. 
Our data support the notion that a 5-HT2B receptor-dependent regulation of serotonin uptake is 
implicated in the control of plasma serotonin levels. 
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Introduction 
 
Primary pulmonary hypertension is a rare but fatal condition characterized by an elevation in 
pulmonary arterial pressure that is associated with pulmonary vasculature remodeling (Loscalzo, 
2001). Several studies have suggested a role for serotonin (5-hydroxytryptamine, 5-HT) in 
pulmonary hypertension (for review see Egermayer et al., 1999). A correlation between high 
plasma serotonin levels and total pulmonary resistance, first observed in a patient with a defect 
in platelet serotonin storage capacity (Hervé et al., 1990), was confirmed in more than 80% of 
pulmonary hypertensive patients (Hosoda, 1994; Hervé et al., 1995; Kéreveur et al., 2000). In 
rats, roles for serotonin in the initiation and progression of monocrotaline induced pulmonary 
hypertension have been suggested since plasma serotonin levels are raised, and pulmonary 
arteries show hyper-reactivity to serotonin. In these experiments, treatments with 5-HT2R 
antagonists inhibited the development of pulmonary hypertension along with a decrease in the 
plasma serotonin concentrations and the number of proliferative cells, substantiating the pivotal 
role of plasma serotonin in the development of monocrotaline- or interleukin-6-induced 
pulmonary hypertension (Miyata et al., 2001). 
 The main peripheral sources of serotonin are as a neurotransmitter and local hormone in 
the gastrointestinal tract enterochromaffin cells and pulmonary neuroepithelial bodies. Blood 
serotonin, which is concentrated in the platelet-dense granules (>99%), is almost absent from 
plasma (nanomolar range) (Da Prada and Picotti, 1979). Defective platelet uptake (Awabdy et 
al., 2003) or release from activated platelets could generate increased plasma serotonin as in 
platelet storage diseases (Hervé et al., 1990). Furthermore, lungs have been reported to remove 
efficiently “free” serotonin from plasma (Gillis and Pitt, 1982). High levels of plasma serotonin 
could, thus, result from an impaired endothelial metabolism that would decrease 5-
hydroxyindole-acetic acid (5-HIAA) levels and/or serotonin uptake. As well as being a 
pulmonary vasoconstrictor, plasma serotonin may exert a co-mitogenic influence on pulmonary 
vascular smooth muscle cells (Liu and Fanburg, 2005) and contribute to both hypoxia-induced 
acute vasoconstriction and chronic vascular remodeling trough various serotonin receptors (5-
HTRs) and the serotonin transporter (SERT).  
 When exposed to few weeks of hypoxia (10% O2), wildtype mice develop pulmonary 
hypertension and lung vascular remodeling recapitulating at least in part the human pathology. 
Smooth muscle and endothelial cells from human and rodent pulmonary arteries express mRNAs 
for 5-HT1B, 5-HT2A, 5-HT7 and 5-HT2BRs and SERT (Ullmer et al., 1995). Mice deficient for 5-
HT1BRs or for SERT are still responsive to chronic hypoxia though the increase in pulmonary 
artery blood pressure and pulmonary vascular remodeling are reduced when compared to control 
mice. Using the chronic-hypoxic-mouse model of pulmonary hypertension, we previously 
reported that the hypoxia-dependent increases in pulmonary blood pressure and lung remodeling 
are totally abolished in mice with genetically or pharmacologically inactive 5-HT2BRs (Launay 
et al., 2002). An interference of the 5-HT2B-/- mice congenital cardiomyopathy to the lung 
hypoxic response has been ruled out since: (i) The cardiac phenotype of 5-HT2B-/- mice is 
characterized by left ventricular dysfunctions, but no apparent right ventricular alterations, (ii) 
the basal pulmonary pressure in 5-HT2B-/- mice is indistinguishable from +/+ mice and (iii) in +/+ 
mice exposed to chronic hypoxia in presence of RS-127445, one of the most selective 5-HT2BR 
antagonist, all tested lung parameters are not significantly different from untreated values, 
clearly demonstrating that the activation of 5-HT2BRs is required for hypoxia-induced pathology 
independently of any prior cardiac phenotype. In both humans and mice, pulmonary 
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hypertension is associated with a substantial increase in 5-HT2BR, 5-HT1BR, but not 5-HT2AR 
expression in pulmonary arteries (Launay et al., 2002). Recently, a heterozygous mutation 
causing premature truncation of the 5-HT2BR protein was found in one patient with 
fenfluramine-associated pulmonary hypertension (Blanpain et al., 2003) that clearly increases 
proliferative index of this mutant receptor (Deraet et al., 2005). However, the link between 5-
HT2BRs and pulmonary hypertension pathophysiology remains to be discovered.  
 Since a correlation between plasma serotonin levels and total pulmonary resistance was 
consistently observed in pulmonary hypertensive patients, we asked whether 5-HTRs could 
participate in the control of plasma serotonin levels. In the present study, we are reporting that 5-
HT2BRs are involved in a carrier-dependent control of plasma serotonin levels in mice. 
JPET #98269          5 
 
Materials and Methods. 
Reagents. LY-266097, 1-(2-chloro-3,4-dimethoxybenzyl)-6-methyl-1,2,3,4-tetrahydro-
9Hpyrido[3,4-b]indole hydrochloride, and RS-127445, 2-amino-4-(4-fluoronaphth-1-yl)-6-
isopropylpyrimidine, were kindly provided by Lilly and Roche companies. BW-723C86, 1-[5-(2-
thienylmethoxy)-1H-3-indolyl]propan-2-amine HCl and all other chemicals were reagent grade, 
purchased from usual commercial sources. The radioactive compound [3H]LY-266097 (925 
GBq/mmol) was provided by Dr J. Würch (Roche, Basel), whereas [3H]serotonin binoxalate (745 
GBq/mmol) and [3H]NaBH4 (2.28 TBq/mmol) were purchased from DuPont NEN. 
 
Hypoxia. The 5-HT2BR mutant mice (-/-) were generated in the 129PAS pure genetic background 
that was used as controls (+/+) (Nebigil et al., 2000). Mice 6 weeks of age (20-25 g) were 
randomly divided into groups of 50% male 50% female mice, maintained either in room air (21% 
O2) or in normobaric chambers (21–23°C) with hypoxic air (10% O2, 90% N2, two or five weeks 
(Launay et al., 2002). Normoxic mice were kept in the similar room with the same 12/12 light-
dark cycle. Classically, groups of 10 mice were treated with vehicle, a highly selective 5-HT2BR 
(full neutral) antagonist RS-127445 at 1 mg/kg/day or dexfenfluramine at the "therapeutic" dose 
of 2.5 mg/kg/day delivered by mini-osmotic pumps (Alzet) from the beginning of the hypoxic 
treatments. All animal care and procedures were in accordance with institutional guidelines and 
European regulations. 
 
Cardiovascular evaluations. Mice were anesthetized with intraperitoneal (i.p.) injection of 
ketamine hydrochloride (60 mg/kg) and xylazine (8 mg/kg). Right ventricular systolic pressure 
(RVSP) was measured by insertion into the right ventricle of a 26-gauge needle connected to a 
pressure transducer. After a blood sample was collected by cardiac puncture for measurements, 
the pulmonary artery was cannulated through an incision in the right ventricle and perfused with 
Earle’s balanced salt solution (37°C, 20 cm H2O pressure).  
 
Lung parameters. Lung vascular bed around pulmonary arteries was collected and prepared for 
culture (Launay et al., 2002). The culture was maintained in DMEM supplemented with 
serotonin-depleted serum (10%) for 24-h, washed with HBSS and grown for 24-h in serum-free 
medium {DMEM/F-12 (1:1) with 5 µg/ml insulin, 5 µg/ml transferrin, 30 nmol/L selenium, 20 
nmol/L progesterone, and 100 µmol/L putrescine} before serotonin uptake was performed.  
 To measure serotonin uptake, after incubation for 1 min with 25, 50, and 100 nmol/L 
[3H]serotonin binoxalate, cells were lysed by addition of 0.1N NaOH and radioactivity was 
counted using liquid scintillation spectrometry. Specific serotonin uptake was assessed as the 
difference between total uptake and uptake in the presence of 1 µmol/L paroxetine. Due to a lack 
of materials, only three concentrations of [3H]serotonin were used, leading only to an estimate of 
the initial rates (1 min uptake) of specific serotonin uptake vs. serotonin concentration. After a 
non-linear regression analysis according to a hyperbolic model (EZ-FIT program), we determined 
the Michaelis-Menten constant (Km) and initial rate (Vi) of serotonin uptake into lung vascular 
cells. 
 Dosage of the 5-HT2BR expression was performed by binding experiments using a 
selective tritiated radioligand (LY-266097). Briefly, cell membranes were prepared by four 
cycles of homogenization (Brinkman P10 disrupter) and centrifugation (48,000 x g for 15 min). 
The assay was established to achieve steady state conditions and to optimize specific binding 
(Kellermann et al., 1996). 50 µg of membrane proteins were incubated with 1 nM [3H]LY-
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266097 at 4°C for 60 min. Nonspecific binding was determined using 1 µM RS-127445. Assays 
were terminated by vacuum filtration through glass fibre filters (GF/B), which had been 
pretreated with 0.1% polyethyleneimine. Total and bound radioactivity was determined by liquid 
scintillation counting. Greater than 80% specific binding was achieved in these assays. 
 For elastolytic activities, conditioned media (380 µL) were incubated at 37°C with 200 µg 
[3H]elastin produced by radiolabeling of purified insoluble elastin from bovine nuchal ligament 
(Elastin Products Co) with [3H]NaBH4 as previously described (Takahashi et al., 1973). After 24 
hours, the radioactivity in 250 µL of the supernatant was determined by liquid scintillation 
spectrometry as a measure of elastolysis. To control for non-enzymatic degradation, radiolabeled 
elastin was incubated with medium from tissue-free cultures. Elastase activity was related to a 
standard curve generated with human leukocyte elastase (0.075 to 5.0 ng) (Elastin Products Co). 
 
Blood parameters. Plasma 3,4-dihydroxyphenylglycol (DHPG) and 5-hydroxyindole-acetic acid 
(5-HIAA) levels were measured by HPLC and serotonin in both plasma and whole blood by 
radioenzymology (Berlin et al., 1995; Kéreveur et al., 2000).  
 
Acute injections. Acute intraperitoneal (i.p.) injections of the preferential 5-HT2BR agonist BW 
723C86 (10 mg/kg), selective 5-HT2BR antagonist RS-127445 (1mg/kg), dexfenfluramine (10 
mg/kg) or nordexfenfluramine (10 mg/kg) were performed on 5-HT2BR+/+ and -/- mice before 
blood was collected by cardiac puncture for measurements over a 30 minutes time period. Pre-
treatment with paroxetine was performed by i.p. injection twice a day of the selective SERT 
blocker paroxetine (1mg/kg) over two days, reducing platelet serotonin uptake by more than 
90%. 
 
Statistics. The reported data represent the mean of individual values±SEM (n=number of 
individuals at the end of treatments as indicated in the text). Comparisons were performed using 
the non-parametric Kruskal-Wallis test. Significance was set at P < 0.0001. This level of 
significance also applies to correlation between individual values, assessed by Kendall rank 
coefficients. For the group comparisons, statistical comparisons were made by one way ANOVA. 
Difference between groups was established using the Bonferonni-Dunn multiple comparison tests 
(P < 0.0001).  
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Results 
The hypoxia-dependent increase in plasma serotonin levels is 5-HT2BR-controlled. 
We previously reported that 5 weeks of hypoxia increased RVSP, media wall thickness, 
pulmonary elastase activity, expression of 5-HT2BRs, and thymidine incorporation in lungs of 
wild-type but not of 5-HT2BR -/- or 5-HT2BR-antagonist-, RS-127445, treated +/+ mice (Launay et 
al., 2002). A progressive increase in RVSP was detected in +/+ mice treated from two to five 
weeks under hypoxia (10% O2) (Fig. 1A). We tested serotonin levels in blood samples of the 
hypoxia-treated mice after acute, two weeks or five weeks of hypoxia. Strikingly, as the 
expression of 5-HT2BRs in lungs (Fig. 1B), plasma serotonin levels (Fig. 1C) were significantly 
increased in +/+ mice after exposure to two weeks of chronic hypoxia, before significant changes 
in remodeling factors could be evidenced (e.g. elastase activity: Fig. 1D) but not in hypoxic 5-
HT2BR -/- mice. No change in whole blood serotonin could be evidenced. 
 This increase in plasma serotonin levels indeed persisted after 5 weeks of hypoxia when 
the pulmonary hypertensive pathology was fully established (Fig. 2A-C) but not in hypoxic 5-
HT2BR -/- or 5-HT2BR-antagonist-, RS-127445, treated +/+ mice. Furthermore, the increase in 
plasma serotonin levels was potentiated in the presence of dexfenfluramine in +/+ mice but not in 
hypoxic 5-HT2BR -/- or RS-127445-treated +/+ mice (Fig. 2C). No significant reduction of whole 
blood serotonin could be observed in hypoxic -/- and +/+ mice. By contrast and as expected, in 
hypoxic and dexfenfluramine exposed -/- and +/+ mice, a significant reduction of whole blood 
serotonin was observed, thus independently of 5-HT2BRs (Fig. 2B). Following the increase in 
plasma serotonin levels, the serotonin main catabolite 5-HIAA was also increased in chronic 
hypoxia dexfenfluramine treated +/+ mice (Fig. 2D). Although not reaching statistical significance 
(P> 0.05), a trend toward a decreased serotonin degradation as expressed by an increased ratio 
between plasma levels of serotonin and 5-HIAA was observed in both hypoxic 5-HT2BR -/- and +/+ 
mice. These first observations suggest a role of 5-HT2BRs in plasma serotonin regulation that 
precedes other pulmonary hypertension parameters. 
 
The hypoxia-dependent increase in plasma serotonin levels is correlated with RVSP and 5-
HT2BR-expression. 
When comparing the plasma serotonin levels and the others parameters affected by hypoxia, we 
observed significant (P < 0.0001) correlations between all the individual plasma serotonin values 
and RVSP values (Fig. 3A), lung 5-HT2BR expression site numbers (Fig. 3B), or plasma 5-HIAA 
values (Fig. 3C). Moreover, the ratios serotonin/5-HIAA were also significantly correlated with 
plasma DHPG values, confirming that these ratios reflect monoamine oxidase A (MAOA) 
activity (Fig. 3E). However, the correlation was not significant between individual plasma and 
whole blood serotonin levels (Fig. 3D). These results further substantiate the evidence that 5-
HT2BRs are required for the regulation of plasma serotonin levels, independently of platelets, 
which store most of the whole blood serotonin.  
 
5-HT2BRs affect lung serotonin uptake activity. 
We determined the parameters of serotonin uptake activity in mouse lung vascular cultures after 
different treatments. Significant variations in the lung uptake activity were detected, which were 
entirely depending on changes in estimated SERT initial rate of uptake (Vi). Chronic hypoxia 
decreased the lung serotonin uptake activity in +/+ mice (Table 1) but not its Km (reflecting SERT 
affinity for serotonin). As expected, chronic hypoxia in the presence of dexfenfluramine nearly 
completely blocked the lung serotonin uptake activity in both +/+ and 5-HT2BR -/- mice (Table 1). 
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A significant increase (27%) in basal normoxic serotonin uptake Vi was observed in 5-HT2BR-/- 
compared to +/+ mice, with no effect of hypoxia (Table 1). No change in expression levels of 
SERT could be detected in any genotype or treatment (189±5 fmoles/mg of protein) as assessed 
by paroxetine binding experiments (not illustrated). These results show that 5-HT2BRs are 
required to regulate hypoxic and basal normoxic lung serotonin uptake activity. 
 
Direct in vivo activation of 5-HT2BRs results in an increase of plasma serotonin levels. 
To test if normoxic mice do respond to activation of 5-HT2BRs, we acutely injected 5-HT2BR 
agonists and assessed the serotonin plasma levels. Over a 30 minutes time period, plasma levels 
were extremely stable after vehicle injection in mice. A significant increase in plasma serotonin 
levels over this control value was observed at 10 minutes after i.p. injection of the 5-HT2BR 
preferential agonist BW-723C86 (10 mg/kg) (76±12% over basal, n=6) in +/+ mice (figure 4A). 
By contrast, in 5-HT2BR -/- mice (figure 4B) or in 5-HT2BR-antagonist, RS-127445- (1 mg/kg, 
n=4) treated +/+ mice (figure 4C), this increase could not be detected. Interestingly, acute i.p. 
injection of nordexfenfluramine (10 mg/kg, n=6) fully mimicked the BW-723C86-dependent 
increase in plasma serotonin levels in timing (peak at 10 minutes) and magnitude (82±17% over 
basal) in +/+ mice, with again no effect on 5-HT2BR inactive mice. However, acute i.p. 
dexfenfluramine injection (10 mg/kg, n=6) produced a faster (5 minutes) and sharper increase in 
plasma serotonin, which was observed in both +/+ and 5-HT2BR inactive mice. The 
dexfenfluramine effect was clearly distinct from that of nordexfenfluramine, since the 
nordexfenfluramine as the BW-723C86 effects on peripheral serotonin release required 5-
HT2BRs. No variation in whole blood serotonin could be detected in this time window in either 
genotype after similar injections (not illustrated). Activation of 5-HT2BRs can thus increase 
plasma serotonin levels. 
 
The in vivo 5-HT2BR-dependent increase in plasma serotonin levels is SERT dependent. 
We tested the effect of SERT inhibition using a pretreatment by the highly selective SERT 
blocker paroxetine or SERT-/- on dexfenfluramine, BW-723C86, or nordexfenfluramine in vivo 
acute i.p. injection. Strikingly, no change in plasma serotonin levels could be detected after acute 
injection of nordexfenfluramine or BW-723C86 when the mice were pretreated by paroxetine 
(1mg/kg, n=6) twice a day for two days, either in +/+, 5-HT2BR -/-, and SERT-/- mice (not 
illustrated). In contrast, a lower but significant increase in plasma serotonin levels over the 
control value was still observed at 5 minutes after dexfenfluramine injection in +/+ mice (62±4% 
of plasma level without paroxetine) (figure 5A) and in 5-HT2BR -/- mice after paroxetine 
treatment (64±8% of plasma level without paroxetine) (figure 5B). No variation in total blood 
serotonin could be detected in this time window in either genotype after similar injections (not 
illustrated). The BW-723C86- and nordexfenfluramine-dependent increases in plasma serotonin 
levels appear entirely 5-HT2BR- and SERT-dependent, whereas that of dexfenfluramine appears 
5-HT2BR-independent and only partially SERT-dependent.  
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Discussion 
We are presenting here the first evidence that 5-HT2BRs are required to control the plasma 
serotonin levels in mice. In chronic +/+ hypoxic mice, the plasma serotonin levels parallel lung 
expression of 5-HT2BR, and are significantly increased before any significant vascular 
remodeling could be evidenced, and potentiated by dexfenfluramine. In mice with either 
permanent (5-HT2BR homozygous mutation) or transient (5-HT2BR selective antagonist) 
inactivation of 5-HT2BRs, plasma serotonin levels are not modified by chronic hypoxia. We also 
observed that the values for plasma serotonin levels and 5-HT2BRs expression are significantly 
correlated. In addition, we show that acute injection of BW-723C86, a preferential 5-HT2BR 
agonist, triggers a rapid increase in plasma serotonin levels, which is entirely SERT-and 5-
HT2BR-dependent as shown by genetic and pharmacologic ablation of either protein and 
mimicked by nordexfenfluramine but not dexfenfluramine. These data demonstrate the 
participation of both 5-HT2BR and SERT in the control of plasma serotonin levels in vivo.  
 An interference of the 5-HT2B-/- mice congenital defects has been ruled out since 
treatment of +/+ mice by RS-127445, the most selective 5-HT2BR antagonist, reproduces the 
results obtained with 5-HT2B-/- mice. The serotonergic anorectic agent and amphetamine 
derivative, dexfenfluramine, increases the risk of developing pulmonary hypertension (Rich et 
al., 2000). In vitro, dexfenfluramine and its main metabolite nordexfenfluramine have been 
shown to inhibit serotonin reuptake and to stimulate its release from brain synaptosomes 
(Mennini et al., 1981). Moreover, both compounds bind to 5-HT2Rs with appreciable affinity. In 
fact, dexfenfluramine binds weakly to rodent and human 5-HT2A,B,CRs but nordexfenfluramine 
behaves as a high affinity agonist for 5-HT2B and 5-HT2CRs and more moderately for 5-HT2ARs 
(Porter et al., 1999; Fitzgerald et al., 2000; Rothman and Baumann, 2002; Setola et al., 2003 and 
supplementary table). In mice, chronic exposure to dexfenfluramine 2.5 mg/kg/day leads to 
complete conversion into nordexfenfluramine with a final plasma concentration of about 500 
nmol/L (Caccia et al., 1985; Launay et al., 2002), fully stimulating 5-HT2BRs but not 5-HT2ARs 
(Supplementary table), 5-HT2CRs being below detection level in the periphery. Chronic effects 
of dexfenfluramine therefore appeared nordexfenfluramine-mediated.  
 The mechanisms leading to hypoxia-induced plasma serotonin elevation might be a 
consequence of platelet defects or of a slower serotonin uptake by platelets due to a kinetic 
change in SERT activity (Awabdy et al., 2003). We did not observed any significant variation in 
whole blood serotonin content (>99% of which is represented by platelets) in hypoxic mice (Fig. 
2B) thus eliminating major changes in serotonin synthesis, platelet number or their serotonin 
uptake capacity. Furthermore, the absence of correlation between individual values of plasma and 
blood serotonin (Fig. 3D) indicates that mechanisms controlling serotonin platelet uptake and 
plasma levels are not coordinately regulated by hypoxia. Moreover, mature platelets express 5-
HT2ARs but not 5-HT2BRs, and ketanserin, a selective 5-HT2AR antagonist, does not significantly 
change pulmonary artery pressure in hypoxic mice (Marcos et al., 2003). Recently, platelets 
serotonin uptake inhibition by both dexfenfluramine and nordexfenfluramine (IC50, 
dexfenfluramine approximately 3  mol/L; nordexfenfluramine approximately 10  mol/L) has 
been reported, but no serotonin efflux occurs at these concentrations (Johnson et al., 2003). 
Together with our chronic in vivo results, these findings indicate that regulation of platelets 
serotonin content and that of plasma serotonin are under different molecular controls in hypoxic 
mice.  
 A change in metabolism might also explain the increase in plasma serotonin levels in 
hypoxic pulmonary hypertension. Lung endothelial cells control serotonin clearance by 
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catabolism into 5-HIAA by MAOA and lung is known as the main site of serotonin removal from 
plasma (Gillis and Pitt, 1982). Low oxygen levels are expected to directly decrease MAO activity 
and thus serotonin metabolism. The non-significant reduction in serotonin degradation observed 
in hypoxic 5-HT2B-/- or +/+ mice (Fig. 3C-E) indicates that 5-HT2BRs have no major contribution 
to the MAOA activity under hypoxia and the increase in plasma serotonin cannot be explained 
solely by changes in MAOA activity. In conclusion, a generalized deficit of the serotonin 
metabolism could not explain the increase in plasma serotonin encountered during hypoxic 
pulmonary hypertension with no changes in whole blood serotonin.  
 Since the lung endothelium is the major site of carrier-mediated peripheral serotonin fast 
removal (Gillis and Pitt, 1982), reduced SERT uptake activity in lungs might also raise plasma 
serotonin levels. Recent evidence obtained by positron emission tomography scan of SERT 
ligands in healthy volunteers confirmed that lung is the main fast high-uptake organs in the body 
(Suhara et al., 1998; Takano et al., 2002). Our result showing a reduced rate of lung serotonin 
uptake upon chronic hypoxia, which is not observed when the 5-HT2BR are inactivated (Table 1), 
agrees with previous reports in lung of hypoxic rats and mice (Jeffery et al., 2000). In perfused 
rat lung, SERT can mediate an efflux of serotonin (James and Bryan-Lluka, 1997) and the 
serotonin efflux caused by SERT substrates (such as amphetamine derivatives) is carrier-
mediated (Hilber et al., 2005). Together, the reduced lung serotonin uptake and the increased 
plasma serotonin levels in hypoxic mice suggest that hypoxia-dependent 5-HT2BR activation can 
trigger the increase in plasma serotonin, probably via a negative regulation of SERT activity. 
Whether this regulation is restricted to lungs remains to be determined. 
 Another site known to express 5-HT2BRs is the gut, which is the main site of peripheral 
serotonin synthesis by enterochromaffin cells. The recent observation that, in perfused rat ileum, 
dexfenfluramine (EC50 around 100  mol/L) or nordexfenfluramine (EC50 around 10  mol/L) 
can increase serotonin levels in the venous effluent strongly support their ability to increase its 
release from the small intestine (Rezaie-Majd et al., 2004). Given the plasma concentrations of 
dexfenfluramine and nordexfenfluramine in sub-micromolar range (Caccia et al., 1985; Launay 
et al., 2002) and the nanomolar affinity of nordexfenfluramine for 5-HT2Rs (Supplementary 
table), a direct action at 5-HT2Rs to the regulation of serotonin release from intestine seems 
unlikely but cannot be totally excluded. 
 In a different experimental in vivo setup, our data show that acute injection of the 5-
HT2BR preferential agonist BW-723C86, as nordexfenfluramine (another preferential 5-HT2B/2CR 
agonist), significantly increases plasma serotonin levels with identical kinetic and 5-HT2BR-
dependency, whereas dexfenfluramine acts with a faster kinetic and generates a serotonin 
increase that is independent of 5-HT2BRs (Fig. 4). Evidence that the mechanism by which 
nordexfenfluramine induces serotonin efflux is different from that underlying dexfenfluramine-
induced release had been previously documented: work in synaptosomes showed that 
nordexfenfluramine acts, at least in part, on the release of a serotonin cytoplasmic pool (Mennini 
et al., 1981), whereas dexfenfluramine can induce a Ca2+-dependent serotonin release from a 
vesicular pool (Gobbi et al., 1998); independent work using microdialysis showed also that 
dexfenfluramine, but not nordexfenfluramine, uses calcium to increase extracellular serotonin 
(Puig de Parada et al., 1995).  
 Although evaluated in the periphery, our work substantiates a dual mode of action for 
these compounds in modulating plasma serotonin levels. Our observations that acute injection of 
dexfenfluramine triggers serotonin releasing effects that are rapid, mainly paroxetine-insensitive 
and independent of 5-HT2BRs, support a rapid mechanism of serotonin release by 
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dexfenfluramine. The modulation by BW-723C86 or nordexfenfluramine of serotonin plasma 
levels is blocked by pharmacological (paroxetine at 1mg/kg, Fig. 5) or genetical (mutant mice, 
not illustrated) SERT inhibition. In humans, similar paroxetine treatment leads to plasma 
concentration less than 500 nmol/L (Lindsay De Vane, 1999). Thus assuming a similar 
bioavailibity in mice, it is unlikely that this concentration could affect 5-HT2A, 5-HT2C, or 5-
HT2BRs (Supplementary table). The elimination of both BW-723C86- and nordexfenfluramine-
induced plasma serotonin increases in 5-HT2BR -/- mice, in 5-HT2BR-antagonist treated +/+ mice, 
by selective SERT blocker and in SERT -/- mice, strongly supports the hypothesis that serotonin 
release is controlled by 5-HT2BRs via a regulation of SERT uptake activity. Reports showing that 
both dexfenfluramine and nordexfenfluramine at  mol/L concentrations generated no efflux of 
serotonin from platelets (Johnson et al., 2003) and that in ileum both compounds increased 
serotonin levels but at concentrations over 10  mol/L (Rezaie-Majd et al., 2004) support the 
implication of other organs such as the lungs in this serotonin release.  
 A 5-HT2BR-dependent SERT phosphorylation (Launay et al., 1998) in vascular 
endothelium could be an essential component of the 5-HT2BR-dependent regulation of plasma 
serotonin independently of platelets. But the molecular pathway leading to the control of SERT 
activity by 5-HT2BRs remains to be molecularly detailed. Our data support the hypothesis that the 
5-HT2BR is an essential partner in signaling pathways regulating the plasma serotonin levels via a 
control of SERT activity. The previous observations that, in response to hypoxia, increases in 
RVSP and in lung vascular remodeling are reduced in mice deficient for SERT, together with our 
finding that paroxetine blocks 5-HT2BR-efflux effects, may explain the paradoxical reports 
showing that some SERT inhibitors have putative beneficial effects in pulmonary hypertension 
(Marcos et al., 2003) whereas injection of serotonin potentiates the development of pulmonary 
hypertension in rats exposed to chronic hypoxia (Eddahibi et al., 1997). Nevertheless, our work 
demonstrates that 5-HT2BR can control plasma serotonin levels in mice and further suggests that 
such a control may participate to other types of pulmonary hypertension in other organisms.  
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Legends for Figures 
 
Figure 1- Kinetic of hypoxia-dependent increase- In +/+ mice exposed to hypoxia from 0 (AH, 
n=10), 2 (H2W, n=10) and 5 (H5W, n=14) weeks, RVSP is progressively increasing (A). Lung 5-
HT2BR expression (B) and plasma serotonin (C) are significantly higher after 2 weeks of hypoxia 
than in vehicle-treated normoxic +/+mice (VE, n=19), but not elastase activity (D). Any statistical 
difference from normoxic untreated control values is indicated by an asterisk (P < 0.0001). 
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Figure 2- Hypoxia-dependent increase in plasma serotonin levels is 5-HT2BR-controlled- In 
+/+ mice exposed to hypoxia for 5 weeks (H5W, n=14), RVSP (A) and plasma serotonin (C) are 
significantly higher than in vehicle-treated normoxic +/+mice (VE, n=19). Simultaneous exposure 
of +/+ mice to hypoxia in the presence of the specific 5-HT2BR antagonist RS-127445 (RS5W, 
n=9) prevents both increases. The presence of dexfenfluramine (DF5W, n=16) with hypoxia 
increases significantly RVSP (A), plasma serotonin (C) and plasma 5-HIAA (D), but decreases 
significantly the whole blood serotonin (B) as compared to normoxic and hypoxic values. By 
contrast, none of the 5-HT2B-/- mice exposed to hypoxia for 5 weeks (n=7) exhibits any 
significant change in RVSP, plasma 5-HIAA or plasma serotonin vs. vehicle-treated normoxic -/- 
mice (n=9), neither in the presence of RS-127445 (n=9) nor dexfenfluramine (n=8). Exposure of 
5-HT2B-/- mice to dexfenfluramine with hypoxia decreases significantly the whole blood serotonin 
and basal normoxic value is above control. Any statistical difference from normoxic untreated 
control values is indicated by an asterisk, and from chronic hypoxia values by a cross (P < 
0.0001). 
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Figure 3- Correlations between individual values of plasma serotonin levels with other 
parameters involved in pulmonary hypertension- Highly significant correlations (P < 0.0001, 
star) are observed between all wildtype individual values at 5 weeks for plasma serotonin levels 
and RVSP (A) (n=58), the number of 5-HT2BR specific binding sites (B) (n=54), plasma 5-HIAA 
levels (C) (n=58). However, the correlation was not significant between individual plasma 
serotonin levels and whole blood serotonin contents (D) (n=58). Furthermore, the serotonin/5-
HIAA plasma ratios were also significantly correlated with plasma DHPG values confirming they 
reflect MAOA activity (E) (n=22). {r=rank of correlation, normoxia (open circles), hypoxia (gray 
circles), hypoxia with dexfenfluramine (open squares), hypoxia with RS-127445 (black 
squares)}.  
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Figure 4- Injection of 5-HT2BR agonists increase plasma serotonin levels- Over a 30 minutes 
time period, measures of plasma serotonin levels are extremely stable after vehicle injection in 
control (+/+ VE), RS-127445- (1 mg/kg, n=4) treated mice (+/+ VERS) and mutant (-/- VE) 
mice. A significant increase (P < 0.0001, star, n=6) in plasma serotonin levels over control values 
is observed at 10 minutes after BW-723C86 (10 mg/kg) (+/+ BW) and nordexfenfluramine (10 
mg/kg) (+/+ NDF) i.p. injection in +/+ mice (A), which is not detected in 5-HT2BR -/- mice (B) or 
in RS-127445 treated +/+ mice (C). However, acute dexfenfluramine i.p. injection (10 mg/kg) 
produced a significant increase (P < 0.0001, star, n=6) in plasma serotonin in +/+ (+/+ DF), RS-
127445 treated +/+ mice (+/+ DFRS) and 5-HT2BR -/- (-/- DF) mice at 5 minutes. 
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Figure 5- Paroxetine blocks 5-HT2BR agonists-dependent increase in plasma serotonin 
levels- A significant increase (star, P<0.0001, n=6) in plasma serotonin levels over control values 
(VEP) is observed at 5 minutes after acute dexfenfluramine i.p. injection in paroxetine pre-treated 
mice in both +/+ (+/+ DFP) (A) and 5-HT2BR -/- (-/- DFP) (B) mice. However, i.p. injection of 
BW-723C86 (+/+ BWP) or nordexfenfluramine (+/+ NDFP) in paroxetine pretreated mice did 
not modified plasma serotonin levels in either +/+, or 5-HT2BR -/- mice. 
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Table 1 
 
Parameters of lung serotonin uptake 
 
    Km     Vi    
     mol/L    pmol/min/mg prot  
VE   4.53±0.58   10.86±0.47  
H5W   4.89±0.48   8.18±1.27 *  
DFH5W  4.54±0.61   0.58±0.08*†  
RSH5W  4.48±0.64   10.30±0.98  
VEKO   4.61±0.69   13.80±0.95*† 
H5WKO  4.64±0.91   13.87±1.50*† 
DFH5WKO  4.71±0.47   1.41±0.12*†  
RSH5WKO  4.43±0.49   13.90±0.93*† 
 
Parameters of serotonin uptake were evaluated in lung explants from normoxic +/+mice (VE), 
hypoxic +/+mice (H5W), hypoxic +/+ mice in the presence of dexfenfluramine (DFH5W), hypoxic 
+/+ mice in the presence of 5-HT2BR-specific antagonist RS-127445 (RSH5W), normoxic -/-mice 
(VEKO), hypoxic -/-mice (H5WKO), hypoxic -/-mice in the presence of dexfenfluramine 
(DFH5WKO) or hypoxic -/-mice in the presence of RS-127445 (RSH5WKO). Any statistical 
difference from normoxic untreated control values is indicated by an asterisk, and from chronic 
hypoxia values by a cross (P < 0.0001). 
